Genomictree Inc.
228760
Rank in Stocks
#19192
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Share Price
$6.60
Market Cap
$162.09M
Change (1 day)
0.95%
Change (1 year)
-50.92%
Country
KR
Trade Genomictree Inc. (228760)
Category
Healthcare
Market Capitalization of Genomictree Inc.(228760)
Market Cap: $162.09M
As of October 2026 Genomictree Inc. has a market cap of $162.09M. This makes Genomictree Inc. the world's 19192nd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Genomictree Inc. from 2017 to 2026
228760 compared with Top 5 Most Popular stocks
